Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero, Margaret A; Malafa, Mokenge P; Behrman, Stephen W; Benson, Al B; Casper, Ephraim S; Chiorean, E Gabriela; Chung, Vincent; Cohen, Steven J; Czito, Brian; Engebretson, Anitra; Feng, Mary; Hawkins, William G; Herman, Joseph; Hoffman, John P; Ko, Andrew; Komanduri, Srinadh; Koong, Albert; Lowy, Andrew M; Ma, Wen Wee; Merchant, Nipun B; Mulvihill, Sean J; Muscarella, Peter; Nakakura, Eric K; Obando, Jorge; Pitman, Martha B; Reddy, Sushanth; Sasson, Aaron R; Thayer, Sarah P; Weekes, Colin D; Wolff, Robert A; Wolpin, Brian M; Burns, Jennifer L; Freedman-Cass, Deborah A

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.